WO2011101831A3 - A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it - Google Patents

A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it Download PDF

Info

Publication number
WO2011101831A3
WO2011101831A3 PCT/IB2011/050719 IB2011050719W WO2011101831A3 WO 2011101831 A3 WO2011101831 A3 WO 2011101831A3 IB 2011050719 W IB2011050719 W IB 2011050719W WO 2011101831 A3 WO2011101831 A3 WO 2011101831A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusidic acid
sodium fusidate
corticosteroid
terbinafine hydrochloride
clobetasone butyrate
Prior art date
Application number
PCT/IB2011/050719
Other languages
French (fr)
Other versions
WO2011101831A2 (en
Inventor
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Kausik Ghosh
Sankar Haridas
Original Assignee
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Kausik Ghosh
Sankar Haridas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulur Subramaniam Vanangamudi, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Kausik Ghosh, Sankar Haridas filed Critical Sulur Subramaniam Vanangamudi
Publication of WO2011101831A2 publication Critical patent/WO2011101831A2/en
Publication of WO2011101831A3 publication Critical patent/WO2011101831A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Abstract

The invention discloses a dermaceutical cream containing Clobetasone Butyrate as a corticosteroid, an antifungal agent in the form of Terbinafine Hydrochloride and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Clobetasone Butyrate and Terbinafine Hydrochloride, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.
PCT/IB2011/050719 2010-02-22 2011-02-22 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it WO2011101831A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN61/MUM/2010 2010-02-22
IN61MU2010 2010-02-22

Publications (2)

Publication Number Publication Date
WO2011101831A2 WO2011101831A2 (en) 2011-08-25
WO2011101831A3 true WO2011101831A3 (en) 2011-12-29

Family

ID=44483422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/050719 WO2011101831A2 (en) 2010-02-22 2011-02-22 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it

Country Status (1)

Country Link
WO (1) WO2011101831A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017368A1 (en) * 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2014036239A2 (en) 2012-08-29 2014-03-06 Unitract Syringe Pty Ltd Controlled delivery drive mechanisms for drug delivery pumps

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045645A1 (en) * 1999-12-23 2001-06-28 Ivrea, Inc. Chitosan biopolymer for the topical delivery of active agents
WO2009063493A2 (en) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210840A (en) 1984-01-18 1987-05-29 Johnson & Johnson Baby Prod Composition comprising synergistic combination of miconazole nitrate and zinc oxide
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
DE69615184T2 (en) 1995-06-07 2002-06-13 Taisho Pharmaceutical Co Ltd FUNGICIDE
US6645473B2 (en) 2000-07-24 2003-11-11 Diana L. Hauan Combination tanning and antifungal topical system for treating tinea versicolor
NL1030438C2 (en) 2005-11-16 2007-05-21 Happy Foot Composition with antifungal properties, use and method.
RU2008135444A (en) 2006-02-02 2010-03-10 Лео Фарма А/С (Dk) COMPOSITION FOR LOCAL USE CONTAINING ANTIBACTERIAL SUBSTANCES
CN100462075C (en) 2006-09-20 2009-02-18 西北农林科技大学 Nanometer miconazole nitrate emulsion medicine and its prepn process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045645A1 (en) * 1999-12-23 2001-06-28 Ivrea, Inc. Chitosan biopolymer for the topical delivery of active agents
WO2009063493A2 (en) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALSARRA ET AL: "Chitosan topical gel formulation in the management of burn wounds", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 45, no. 1, 1 July 2009 (2009-07-01), pages 16 - 21, XP026116180, ISSN: 0141-8130, [retrieved on 20090402], DOI: 10.1016/J.IJBIOMAC.2009.03.010 *
RAMSAY C A ET AL: "The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate", JEADV. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 7, no. SUPPL. I, 1 July 1996 (1996-07-01), pages S15 - S22, XP002582785, ISSN: 0926-9959, [retrieved on 20021011], DOI: 10.1016/0926-9959(96)00032-3 *
RAVI KUMAR M N V: "A review of chitin and chitosan applications", REACTIVE & FUNCTIONAL POLYMERS, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 46, no. 1, 1 November 2000 (2000-11-01), pages 1 - 27, XP004224437, ISSN: 1381-5148, DOI: 10.1016/S1381-5148(00)00038-9 *

Also Published As

Publication number Publication date
WO2011101831A2 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
WO2011026094A3 (en) Stable aerosol topical foams comprising a hypochlorite salt
MX354480B (en) Foamable benzoyl peroxide compositions for topical administration.
EP3329965A3 (en) Dosing regimen of anti-alpha4beta7-antikörper
EP3458074A4 (en) COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
WO2011107755A3 (en) Immediate/delayed drug delivery
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
EP3658134A4 (en) Liposome compositions comprising weak acid drugs and uses thereof
WO2014030770A3 (en) Copolymer having carbosiloxane dendrimer structure and hydrophilic group
WO2011128236A3 (en) Process for preparing diluted agrochemical spray formulations with improved drift control
WO2010109425A3 (en) A medicinal steroids cream and a process to make it
WO2014116876A8 (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
WO2016012417A3 (en) Deodorant preparations comprising polyquaternium polymers
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
EP2910563A8 (en) Triterpene derivative and its anti-influenza use
WO2011100975A3 (en) Stabilized tacrolimus composition
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2014121048A3 (en) Topical compositions and methods for making and using same
WO2013034527A3 (en) Hair fixative compositions
MX2012007227A (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture.
WO2011101831A3 (en) A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it
WO2014203137A3 (en) Pharmaceutical compositions of tamsulosin or salts thereof
WO2014006636A3 (en) Stable compositions of fesoterodine
WO2012004691A3 (en) Pharmaceutical formulations of rasagiline
WO2011101828A8 (en) A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2010119367A3 (en) A medicinal cream made using hydrocortisone acetate and a process to make the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11711393

Country of ref document: EP

Kind code of ref document: A2